Unilateral vocal fold paralysis (UVFP) affects an estimated 31 per 100,000 adults annually, resulting from recurrent laryngeal nerve injury during thyroidectomy, anterior cervical spine surgery, mediastinal oncology, or viral neuritis. Left untreated, glottic insufficiency causes breathy dysphonia, vocal fatigue, and significant aspiration risk, with injection medialization laryngoplasty (IML) and framework Type I thyroplasty achieving complete glottic competence in 84% to 92% of surgical candidates, while reducing Maximum Phonation Time (MPT) deficits by an average of 6 to 9 seconds. The metrics below derive from surgical registries and clinical guidelines compiled by the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), the Journal of Voice, Laryngoscope, and the National Institute on Deafness and Other Communication Disorders (NIH/NIDCD).
TL;DR
- Unilateral vocal fold paralysis annual incidence stands at 28 to 34 per 100,000 individuals, with iatrogenic surgical trauma accounting for 46% to 56% of presentations (AAO-HNS).
- Thyroid and parathyroid surgeries represent the leading iatrogenic etiology, causing vocal fold paresis or paralysis in 2.3% to 5.2% of operations (Journal of Voice).
- Anterior cervical discectomy and fusion (ACDF) carries a postoperative temporary recurrent laryngeal nerve injury rate of 3.4% to 8.1% (Laryngoscope).
- Early in-office injection medialization laryngoplasty performed within 3 to 6 months of injury reduces the need for permanent open thyroplasty by 48% (AAO-HNS).
- Hyaluronic acid and carboxymethylcellulose temporary injectable gels maintain functional glottic volume for 3 to 6 months during nerve regeneration windows (Journal of Voice).
- Calcium hydroxylapatite (Radiesse Voice) and micronized autologous fascia provide long-term injectable medialization lasting 12 to 24 months (Laryngoscope).
- Type I external framework thyroplasty (Isshiki) with Silastic or titanium implants achieves successful glottic closure in 88.5% of permanent paralysis cases (AAO-HNS).
- Maximum Phonation Time (MPT) increases post-medialization from a preoperative average of 5.8 seconds to 14.6 seconds (Journal of Voice).
- Voice Handicap Index (VHI-10) scores improve dramatically, dropping from a mean of 28.4 (severe impairment) down to 9.2 (mild/normal) (Laryngoscope).
- Aspiration of thin liquids on modified barium swallow testing is eliminated in 76% to 84% of paralyzed patients following glottic medialization (AAO-HNS).
- Arytenoid adduction or adduction arytenopexy combined with thyroplasty is required in 18% to 26% of patients presenting with wide posterior glottic gaps (>3 mm) (Journal of Voice).
- Spontaneous neural regeneration with functional vocal fold mobility recovery occurs in 38% to 54% of non-transected neuropraxic injuries within 9 to 12 months (NIH/NIDCD).
1. Etiology, Surgical Risk Factors, and Epidemiology
Vocal fold paralysis arises from disruption of the vagus nerve or its recurrent laryngeal branch, leading to denervation atrophy of the thyroarytenoid and lateral cricoarytenoid muscles. Iatrogenic surgical trauma during endocrine, thoracic, and spinal interventions represents the overwhelming majority of etiologies evaluated alongside vocal fold nodules statistics.
| Etiological Category | Proportion of UVFP Cases | Primary Source |
|---|---|---|
| Iatrogenic Surgical Trauma (Thyroid, Spine, Thoracic) | 51.4% | AAO-HNS |
| Malignant Neoplasm (Lung, Esophagus, Thyroid) | 21.8% | Journal of Voice |
| Idiopathic / Post-Viral Neuritis | 14.2% | Laryngoscope |
| Endotracheal Intubation Mechanical Injury | 7.4% | NIH/NIDCD |
| Non-Surgical External Neck / Chest Trauma | 3.6% | AAO-HNS |
| Central Neurological Stroke / Skull Base Lesion | 1.6% | Journal of Voice |
Source: American Academy of Otolaryngology-Head and Neck Surgery
2. Diagnostic Laryngeal Electromyography (LEMG) and Prognosis
Laryngeal electromyography (LEMG) samples motor unit potentials from the thyroarytenoid-lateral cricoarytenoid muscle complex to differentiate mechanical arytenoid subluxation from true neural denervation. The presence of voluntary recruitment potentials within 6 months predicts spontaneous recovery.
| LEMG Finding (Within 6 Months) | Functional Recovery Rate | Clinical Prognostic Value |
|---|---|---|
| Normal / Mildly Reduced Motor Unit Recruitment | 88.4% | Favorable Prognosis |
| Polyphasic Reinnervation Potentials Present | 74.2% | Active Regeneration |
| Fibrillation Potentials / Positive Sharp Waves Only | 16.8% | Poor (Denervation) |
| Complete Electrical Silence (Fibrotic Atrophy) | 4.2% | Permanent Non-Recovery |
| LEMG Accuracy for Spontaneous Recovery at 6mo | 84.6% | Journal of Voice |
| Spontaneous Clinical Mobility Recovery Overall | 44.8% | Laryngoscope |
Source: Journal of Voice (The Voice Foundation)
3. Injection Medialization Laryngoplasty Materials and Techniques
Injection laryngoplasty can be performed in-office under local topical anesthesia via transoral, transcricothyroid, or transthyroid cartilage approaches. Injectable biomaterials vary based on resorption rates and viscoelastic match to native vocal fold lamina propria, following biomechanical principles detailed in voice prosthesis laryngectomy statistics.
| Injectable Biomaterial | Average Dwell Duration | Complete Glottic Closure |
|---|---|---|
| Carboxymethylcellulose Gel (Prolaryn Gel) | 2 - 3 months | 86.4% |
| Cross-Linked Hyaluronic Acid (Restylane/Juvederm) | 4 - 6 months | 88.2% |
| Micronized Acellular Dermal Matrix (Cymetra) | 9 - 14 months | 84.8% |
| Calcium Hydroxylapatite (Prolaryn Plus) | 12 - 24 months | 89.6% |
| Autologous Micro-Lipoinjection (Fat Graft) | 18 - 36 months | 82.4% |
| Early Injection Reduction in Secondary Thyroplasty | 48.2% | Laryngoscope |
Source: The Laryngoscope
4. Type I Thyroplasty and Arytenoid Adduction Surgical Outcomes
Framework surgery (Isshiki Type I medialization) provides lifelong structural repositioning without relying on material resorption dynamics. For large posterior chinks caused by paralyzed lateralized vocal processes, combining thyroplasty with arytenoid adduction or adduction arytenopexy achieves comprehensive glottic competence.
| Surgical Framework Procedure | Complete Glottic Closure Rate | Complication Rate |
|---|---|---|
| Type I Thyroplasty (Silastic Implant) | 89.2% | 3.8% |
| Type I Thyroplasty (VoCoM Titanium Clamp) | 91.4% | 2.9% |
| Combined Thyroplasty + Arytenoid Adduction | 94.6% | 6.4% |
| In-Office Revision / Implant Repositioning | 4.2% | N/A |
| Implant Extrusion / Airway Compromise | 0.8% | Rare Emergency |
| Postoperative Aspiration Elimination Rate | 81.4% | Clinical Swallowing Study |
Source: American Academy of Otolaryngology-Head and Neck Surgery
5. Acoustic, Aerodynamic, and Quality of Life Metrics
Objective vocal restoration measures aerodynamic phonation efficiency and perceptual speech quality. Medialization eliminates glottic air wastage, dramatically expanding maximum phonation duration and restoring vocal intensity for occupational and social communication.
| Vocal Acoustic / Functional Metric | Preoperative Baseline | Postoperative (12 Months) |
|---|---|---|
| Maximum Phonation Time (MPT) on /a/ | 5.8 seconds | 14.6 seconds |
| Mean Phonation Flow Rate (aerodynamic) | 385 mL/sec | 162 mL/sec (Normal: 100-200) |
| Voice Handicap Index (VHI-10) Score | 28.4 / 40 | 9.2 / 40 |
| Acoustic Jitter (Frequency Perturbation) | 3.8% | 1.2% (Normal: <1.0%) |
| Acoustic Shimmer (Amplitude Perturbation) | 7.4% | 2.8% (Normal: <3.8%) |
| Return to Professional Voice Employment | 42.0% | 84.8% |
Source: Journal of Voice
Summary: Vocal Fold Paralysis & Injection Medialization by the Numbers
| Metric | Value | Source |
|---|---|---|
| Annual UVFP Population Incidence | 31 / 100,000 | AAO-HNS |
| Iatrogenic Surgical Trauma Share | 51.4% | AAO-HNS |
| Thyroidectomy Paralysis Incidence | 3.4% | Journal of Voice |
| ACDF Spine Surgery RLN Injury Rate | 5.2% | Laryngoscope |
| Early Injection Thyroplasty Reduction | 48.2% | Laryngoscope |
| Spontaneous Nerve Recovery (Neuropraxia) | 44.8% | NIH/NIDCD |
| LEMG Prognostic Accuracy at 6 Months | 84.6% | Journal of Voice |
| Injection Complete Glottic Closure | 88.2% | Laryngoscope |
| Type I Thyroplasty Closure Rate | 90.4% | AAO-HNS |
| Combined Thyroplasty + Arytenoid Adduction | 94.6% | Journal of Voice |
| Mean MPT Improvement Post-Surgery | +8.8 seconds | Journal of Voice |
| VHI-10 Score Reduction (Improvement) | -19.2 points | Laryngoscope |
| Aspiration Clearance on MBS Swallow | 81.4% | AAO-HNS |
| Phonation Flow Rate Normalization | 162 mL/sec | Journal of Voice |
| Titanium vs Silastic Implant Success | 91.4% vs 89.2% | AAO-HNS |
| Implant Extrusion Adverse Event Rate | 0.8% | Laryngoscope |
| Return to Work Rate Post-Medialization | 84.8% | Journal of Voice |
| Voice Therapy Alone Benefit Rate | 38.5% | AAO-HNS |
Methodology and Sources
The statistics synthesized in this benchmark derive from clinical trial databases, peer-reviewed otologic journals, and specialty consensus statements. Primary data sources include:
- American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS)
- Journal of Voice (The Voice Foundation)
- The Laryngoscope
- NIH National Institute on Deafness and Other Communication Disorders
- Data watch: Retrospective injection medialization cohorts frequently combine diagnostic paresis (partial mobility impairment) with complete paralysis; paretic folds have a 25% higher rate of spontaneous recovery, which can artificially inflate early injection “cure” rates if electromyographic confirmation is omitted.
Last updated: October 13, 2026. Clinical benchmarks and surgical registries are monitored on a quarterly basis to incorporate newly published randomized controlled trials and longitudinal cohort updates.